Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

The purpose of this trial is to see how well a new trial drug (degarelix) works in terms of
reducing the size of the prostate volume in prostate cancer patients who are scheduled to
undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving
radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer
are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to
reduce the size of the prostate and thereby decrease the required radiation field and enable
a more safe and effective treatment. In this trial, hormone therapy will be given for three
months and patients will be randomly selected (like flipping a coin) to receive either
Degarelix given alone or a standard hormone therapy (combination of goserelin and
bicalutamide) The prostate size will be measured by ultra sound at the beginning and at the
end of the trial and patients will be required to come to the clinic for 5 or 6 visits
during the three months.